Novavax Q3 Earnings & Sales Beat, Stock Falls 6% on '24 View Cut
NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, ...
Novavax Inc (NVAX) Q3 2024 Earnings Call Highlights: Strategic Partnerships and Financial ...
Novavax Inc (NVAX) reports increased product sales and a strong cash position, while revising revenue guidance and navigating ...
Novavax stock plunges after quarterly earnings, but company sees hope in licensing deals
The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...
Novavax Stock is Slipping After the Vaccine Maker Cut its Outlook Again
Novavax shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter ...
Novavax to Participate in Jefferies London Healthcare Conference
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...
Novavax Lowers 2024 Forecast Despite Q3 Revenue Beat, Stock Falls
On Tuesday, Novavax Inc (NASDAQ:NVAX) reported third-quarter 2024 sales of $84.5 million, compared to $186.99 million a year, ...
Novavax (NVAX) Reports Q3 Loss, Tops Revenue Estimates
Novavax (NVAX) delivered earnings and revenue surprises of 12.64% and 47.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...
FDA Gives Green Signal To Novavax's COVID-19-Influenza Combo Vaccine Late-Stage Trial
On Monday, the FDA removed the clinical hold on Novavax Inc.’s (NASDAQ:NVAX) Investigational New Drug (IND) application for ...
Novavax to Report Q3 Earnings: Here's What to Expect
On NVAX's third-quarter earnings call, investors will likely seek updates on management???s ongoing discussions with the FDA ...
Yahoo Finance2d
U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
GAITHERSBURG, Md., Nov. 11, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based ...
Novavax: Q3 Earnings Snapshot
NVAX) on Tuesday reported a loss of $121.3 million in its third quarter. On a per-share basis, the Gaithersburg, Maryland-based company said it had a loss of 76 cents. The results exceeded Wall Street ...